Oxytocin Acetate 50-56-6

98% up by HPLC, USP, EP, CEP

Product categories

New Products

Product Details

Product Information

Product name	Oxytocin Acetate
CAS No.	50-56-6
Molecular Formula	C43H66N12O12S2
Molecular Weight	1007.33
Molecule Structure
Quality Standard	98% up by HPLC, USP/EP, CEP
Appearance	White powder

COA of Oxytocin Acetate

Items	Specification	Results
Appearance	White powder	Conforms
Solubility	Soluble in water or 1% acetic acid at a concentration of ≥1mg/ml to give a clear, colorless solution	Conforms
Identity by HPLC	The retention is same with the reference substance	Conforms
Amino acid composition	gly:0.85～1.10 pro:0.85～1.10 leu:0.85～1.10 cys:1.65～2.20 asn:0.85～1.10 gln:0.85～1.10 ile:0.85～1.10 tyr:0.85～1.10	1.02 1.06 1.01 1.88 0.96 1.01 0.99 1.02
pH	3.0～6.0	5.16
Specific optical rotation	c=1,1%hac	-21.2°
Purity	≥98.0%	99.12%
Related substance(by hplc)	total impurities(%)≤2.0% largest single impurity(%)≤1.0%	0.88% 0.55%
Acetate content(by hplc)	≤12.0%	6.7%
Water	≤8%	5.7%
Peptide content (n%)	≥80.0%	87.6%
Bacterial endotoxins	≤70iu/mg	Conforms
Residual organic solvents	acetonitrile ≤0.041%(by gc) dmf ≤0.088%(by gc) meoh ≤0.3% (by gc) tfa ≤0.1% (by hplc) dcm ≤0.06% (by gc) mecn ≤0.041% (by gc)	Conforms
Assay	95%～105%	99.3%
Conclusion	Complies with the standard.

Usage

Function of Oxytocin Acetate

Oxytocin acetate is a peptide hormone, secreted by the posterior pituitary gland, synthesized by the paraventricular nucleus and supraoptic nucleus of the hypothalamus, composed of 9 amino acids, and transported to the neurohypophysis at a rate of 2 mm to 3 mm per day freed. The cysteine (Cys) residues at positions "1" and "6" form a 6-peptide ring structure in the form of disulfide bonds.

(1) Effect on mammary glands: The breast during lactation continuously secretes milk under the action of prolactin, which is stored in the acinar glands of the breast. Oxytocin can shrink the myoepithelial-like cells around the breast acinar, and promote the breast milk with the lactating function.

(2) The effect on the uterus: Oxytocin has a strong effect on promoting the contraction of the uterus, but the pregnant uterus is more sensitive. Estrogen can increase the sensitivity of the uterus to oxytocin, while progesterone does the opposite.

Hot Tags : oxytocin powder Oxytocin acetate Oxytocin peptide polypeptide powder polypeptide supplier polypeptide manufacture

Send A Message

Related Products

LIRAGLUTIDE 204656-20-2

Product Information Product name Liraglutide Sequence H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- Glu-Gly-Gln-Ala-Ala-Lys[N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]- -Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH CAS No. 204656-20-2 Molecular Formula C172H265N43O51 Molecular Weight 3751.20 Storage 2~8℃ Appearance White to off-white crystalline powder COA of Liraglutide Test Specification Results Appearance: White to off-white crystalline powder or lumps White powder Identity: 3751.2±1.0 3751.1 Purity (By HPLC) : Not Less than 98.0%; 99.51% Residual solvents: ≤0.25%total; ≤0.1%individual; ≤0.01%CH2CN Complies Related Peptide Total Impurity ≤ 2.0% Largest Single Impurity ≤ 1.0% TI =0.41% LSI =0.25% Peptide Content: Not Less than 85.0% 87.7% Water (K.F.): Not more than 5% 4.2% Acetate acid: Not more than 10% 8.1% Bacterial Endotoxins Not more than 50IU/mg Complies Usage Function and Usage of Liraglutide 204656-20-2 1、 Type 2 diabetes Liraglutide improves control of blood glucose.It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion. In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes: · Liraglutide acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia. · Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies). · Liraglutide decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride. · Liraglutide lowers blood triglyceride levels. 2、Obesity Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.